These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 23567084)

  • 1. NS5A inhibitors in the treatment of hepatitis C.
    Pawlotsky JM
    J Hepatol; 2013 Aug; 59(2):375-82. PubMed ID: 23567084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NS5A Resistance: Clinical Implications and Treatment Possibilities.
    Calleja JL; Llerena S; Perelló C; Crespo J
    AIDS Rev; 2016; 18(1):15-22. PubMed ID: 26991826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.
    Zhou N; Han Z; Hartman-Neumann S; DeGray B; Ueland J; Vellucci V; Hernandez D; McPhee F
    J Antimicrob Chemother; 2016 Dec; 71(12):3495-3505. PubMed ID: 27605597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
    Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H
    J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
    Hong CM; Liu CJ; Yeh SH; Chen PJ
    J Formos Med Assoc; 2017 Apr; 116(4):295-299. PubMed ID: 28034492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
    Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
    J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
    Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
    Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.
    Fourati S; Guedj J; Chevaliez S; Nguyen THT; Roudot-Thoraval F; Ruiz I; Soulier A; Scoazec G; Varaut A; Poiteau L; Francois M; Mallat A; Hézode C; Pawlotsky JM
    Aliment Pharmacol Ther; 2018 Mar; 47(5):665-673. PubMed ID: 29271114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4.
    McCormick AL; Wang L; Garcia-Diaz A; Macartney MJ; Webster DP; Haque T
    Antivir Ther; 2015; 20(1):81-5. PubMed ID: 24621453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
    Horváth G; Halász T; Makara M; Hunyady B
    Orv Hetil; 2015 May; 156(21):841-8. PubMed ID: 26038991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
    Fedorchenko SV; Martynovych T; Klimenko Z; Solianyk I
    J Med Virol; 2021 Aug; 93(8):4975-4981. PubMed ID: 33704798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
    Hernandez D; Yu F; Huang X; Kirov S; Pant S; McPhee F
    Adv Ther; 2016 Jul; 33(7):1169-79. PubMed ID: 27287851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.
    Gentile I; Buonomo AR; Borgia G
    Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1033-43. PubMed ID: 25074011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclatasvir: potential role in hepatitis C.
    Lee C
    Drug Des Devel Ther; 2013; 7():1223-33. PubMed ID: 24204123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of daclatasvir in hepatitis C virus.
    Izumi N
    Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1025-31. PubMed ID: 25059552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daclatasvir for the treatment of chronic hepatitis C virus infection.
    Temesgen Z; Rizza SA
    Drugs Today (Barc); 2015 May; 51(5):277-88. PubMed ID: 26097901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus NS5A inhibitors and drug resistance mutations.
    Nakamoto S; Kanda T; Wu S; Shirasawa H; Yokosuka O
    World J Gastroenterol; 2014 Mar; 20(11):2902-12. PubMed ID: 24659881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.